JYNNEOS™疫苗作为猴痘暴露后预防的有效性:使用真实世界疫情数据面临的挑战
在纽约市猴痘疫情期间,评估单剂JYNNEOS™疫苗皮下接种≤14天作为暴露后预防的效果。采用目标试验模拟分析549名暴露者,调整暴露风险和种族/民族后,PEPL有效性19%(95%CI -54%至57%),PEPF有效性-7%(95%CI -144%至53%);传统分析分别为78%(95%CI 50%至91%)和73%(95%CI 31%至91%)。结论认为真实世界数据评估PEP效果具挑战性,传统方法因不朽时间偏倚高估效果。
要点
- 目标试验模拟显示PEPL有效性19%(95%CI -54%至57%),PEPF有效性-7%(95%CI -144%至53%)。
- 传统分析显示PEPL有效性78%(95%CI 50%至91%),PEPF有效性73%(95%CI 31%至91%)。
- 传统方法因不朽时间偏倚高估PEP有效性。
核心结论
- 使用真实世界疫情数据确定PEP有效性具有挑战性;纽约市获取PEP的时间与观察到的潜伏期相结合,导致传统方法高估PEP有效性。
- 目标试验模拟虽然因样本量小而产生宽置信区间,但避免了不朽时间偏倚。
- 这些评估结果不能用作PEP有效性的可靠估计,但为未来评估提供了重要的方法学考虑。
研究设计与样本
- 在2022年5月22日至2022年8月24日期间,对接触过病例的个体评估单剂JYNNEOS™疫苗皮下接种≤14天作为暴露后预防预防猴痘疾病的有效性。
- 个体在暴露后21天内评估猴痘。
- 开展观察性研究,模拟从暴露后每天开始的嵌套“目标”随机试验序列。
- 结果根据暴露风险和种族/民族进行调整。
- 基于最后暴露日期(PEPL)和首次暴露日期(PEPF)分别进行分析。
主要发现
- 未接受PEPL的病例中,从最后暴露到症状出现的中位时间(潜伏期)为7天(范围1-16)。
- 接受PEPL的时间为7天(范围0-14)。
- 在549名个体中,目标试验模拟调整后PEPL有效性为19%(95%CI -54%至57%),PEPF有效性为-7%(95%CI -144%至53%)。
- 传统分析调整后PEPL有效性为78%(95%CI 50%至91%),PEPF有效性为73%(95%CI 31%至91%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 目标试验模拟因样本量小而产生宽置信区间。
- 这些评估结果不能用作PEP有效性的可靠估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: JYNNEOSTM vaccine has been used as post-exposure prophylaxis (PEP) during a mpox outbreak in New York City (NYC). Data on effectiveness are limited. METHODS: Effectiveness of a single dose of JYNNEOSTM vaccine administered subcutaneously ≤ 14 days as PEP for preventing mpox disease was assessed among individuals exposed to case-patients from May 22, 2022-August 24, 2022. Individuals were evaluated for mpox through 21 days post-exposure. An observational study was conducted emulating a sequence of nested "target" randomized trials starting each day after exposure. Results were adjusted for exposure risk and race/ethnicity. Analyses were conducted separately based on last (PEPL) and first (PEPF) exposure date. We evaluated the potential to overestimate PEP effectiveness when using conventional analytic methods due to exposed individuals developing illness before they can obtain PEP (immortal time bias) compared to the target trial. RESULTS: Median time from last exposure to symptom onset (incubation period) among cases that did not receive PEPL was 7 days (range 1-16). Time to PEPL receipt was 7 days (range 0-14). Among 549 individuals, adjusted PEPL and PEPF effectiveness was 19 % (95 % Confidence Interval [CI], -54 % to 57 %) and -7% (95 % CI, -144 % to 53 %) using the target trial emulation, respectively, and 78 % (95 % CI, 50 % to 91 %) and 73 % (95 % CI, 31 % to 91 %) using conventional analysis. CONCLUSIONS: Determining PEP effectiveness using real-world data during an outbreak is challenging. Time to PEP in NYC coupled with the observed incubation period resulted in overestimated PEP effectiveness using a conventional method. The target trial emulation, while yielding wide confidence intervals due to small sample size, avoided immortal time bias. While results from these evaluations cannot be used as reliable estimates of PEP effectiveness, we present important methodologic considerations for future evaluations.
引用
- Rosen JB, Arciuolo RJ, Pathela P, et al. JYNNEOS™ effectiveness as post-exposure prophylaxis against mpox: Challenges using real-world outbreak data. Vaccine. 2024. PMID: 38218669. doi:10.1016/j.vaccine.2023.12.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。